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Abstract
Summary In this meta-analysis of all Merck-conducted,
placebo-controlled clinical trials of alendronate, the occur-
rence of AF was uncommon, with most studies reporting
two or fewer events. Across all studies, no clear association
between overall bisphosphonate exposure and the rate of
serious or non-serious AF was observed.
Introduction To explore the incidence of atrial fibrillation
(AF) and other cardiovascular endpoints in clinical trials of
alendronate.
Methods All double-blind, placebo-controlled studies of
alendronate 5, 10, or 20 mg daily, 35 mg once-weekly,
35 mg twice-weekly, and 70 mg once-weekly of at least
3 months duration conducted by Merck were included in
this meta-analysis. The primary method of analysis was
exact Poisson regression. Estimated relative risk (RR) of
alendronate versus placebo and the associated 95% confi-
dence interval was derived from a model that included
number of episodes with factors for treatment group and
study and an offset parameter for number of person-years
on study.
Results Of 41 studies considered, 32 met all criteria for
inclusion in the analysis (participants—9,518 alendronate,
7,773 placebo). Estimated RR for all AF events was 1.16
(95% CI=0.87, 1.55; p=0.33). Most trials had two or fewer
AF events. The RR of AF classified as a serious adverse
event was 1.25 (95% CI=0.82, 1.93; p=0.33), but became
0.97 (95% CI=0.51, 1.85) when the clinical fracture cohort
of the Fracture Intervention Trial was excluded, indicating
that results were driven by events in that study. Estimated
RRs for other cardiovascular endpoints were less than 1.
Conclusions The incidence of atrial fibrillation was low in
Merck clinical trials of alendronate and was not signifi-
cantly increased in any single trial nor in the meta-analysis.
Based on this analysis, alendronate use does not appear to
be associated with an increased risk of atrial fibrillation.
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Introduction
Atrial fibrillation is the most common sustained cardiac
arrhythmia, affecting more than 2 million individuals in the
USA [1, 2]. Because the population is aging and age 65 or
greater is a strong risk factor for AF, the prevalence of AF
is expected to increase to nearly 16 million cases by 2050
[2]. Extrapolation from Framingham cohort data suggests
one in four adults will experience at least one episode of AF
in their lifetime [3].
Bisphosphonates are the most widely used class of drugs
for the treatment of osteoporosis. Black et al. [4]r e p o r t e da n
increased risk of serious atrial fibrillation (AF) adverse
experiences (SAEs) in a study of once-yearly intravenous
zoledronic acid for the treatment of postmenopausal osteo-
porosis. In that study, the number of participants with AF
SAEs was significantly greater with zoledronic acid than
with placebo [50 (1.3%) vs. 20 (0.5%) participants,
p<0.001]. As noted in a letter to the editor by Cummings
et al., published concurrently, there was a nominally but not
significantly increased risk of AF SAEs with alendronate, an
oral bisphosphonate, for participants in the Fracture Inter-
vention Trial (FIT) [Relative Risk (RR)=1.51, 95% CI=
0.97, 2.40, p=0.07 for AF SAEs for alendronate compared
with placebo; RR=1.14, 95% CI=0.83, 1.57, p=0.42 for all
(serious and non-serious) AF AEs] [5]. Since these two
reports, others have conducted meta-analyses of data from
ibandronate clinical trials as well as from the published
literature and from retrospective studies to examine the
risk for AF in patients taking bisphosphonates for the
treatment of osteoporosis [6–11]. The report of an
increased risk of AF with zoledronic acid and the
observations regarding the original alendronate FIT data
prompted us to explore, using both published and
unpublished data, the incidence of AF and other related
cardiovascular (CV) endpoints with alendronate compared
with placebo in clinical trials conducted by Merck. In
addition to the meta-analysis, information is summarized
on myocardial infarctions (MIs) and CV deaths from the
FIT trial, the only trial to adjudicate CV AEs.
Methods
Objective
The primaryobjective ofthismeta-analysis wastoexplorethe
incidence of AF (atrial fibrillation or atrial flutter) AEs for
participants in alendronate clinical trials and to compare the
relative risk of these events between alendronate-treated and
placebo-treated participants. Secondary objectives were to
explore the incidence of all cardiac arrhythmias, non-
hemorrhagic cerebrovascular accidents (CVA), and conges-
tive heart failure (CHF) in these clinical trials and to compare
the relative risk of these events between alendronate-treated
and placebo-treated participants. In addition, the possible
association of alendronate with MI and CV death in FIT, the
only trial with adjudicated CVevents, was explored.
Analyses
All the analyses in this study were predefined. There was a
full meta-analysis protocol prepared and approved by all
authors before any analyses were conducted. Each partic-
ipant experiencing an endpoint was only counted once for
that endpoint; however, participants with more than one
type of endpoint could be counted separately for each
endpoint. All events of AF reported as AEs by the study
investigator were included in the analysis. All events of AF
and other cardiac arrhythmias reported for FIT were
adjudicated at the time of the study by a physician blinded
to treatment allocation; a data and safety monitoring
committee reviewed the unblinded safety data periodically
throughout the trial. Cardiac arrhythmia and AF event data
from all other studies were reported as AEs without
additional adjudication. AEs were classified as serious if
they met the regulatory definition of a “serious” AE as
reported by the study investigator. For these studies, an
SAE was defined as any AE that results in death, is life
threatening, results in a persistent or significant disability/
incapacity, results in or prolongs an existing hospitalization,
is a congenital anomaly/birth defect (in offspring of
patient), is a cancer, or is an overdose (whether accidental
or intentional). Events included both new events in
participants with no prior history of AF and worsening
events (i.e., recurrent AF or increasing clinical signs/
symptoms in participants with chronic AF). To insure
complete accounting, AEs of atrial fibrillation and the
closely related AEs of atrial flutter are grouped as the
primary endpoint of the analysis.
Other endpoints that were explored due to their potential
association with AF were the incidence of all cardiac
arrhythmias, non-hemorrhagic CVA, and CHF (see Online
supplement for terms used to identify events).
Choice of studies and treatment groups
All Merck-conducted, double-blind, placebo-controlled
studies of alendronate 5 mg daily, 10 mg daily, 20 mg
daily, 35 mg once-weekly, 35 mg twice-weekly, and 70 mg
once-weekly of at least 3 months duration were included in
this analysis (Table 1); the few short duration trials were
234 Osteoporos Int (2012) 23:233–245Table 1 List of studies considered in alendronate meta-analysis
Study Included
in meta-
analysis
If excluded—reason
for exclusion
Length
of study
Percent
women
Average age
for study (in
years)
Citation
026 Yes 2 years 100 63.0 Chesnut CH 3rd et al. Am J Med 1995; 99:144–152.
Stock JL, et al. Am J Med 1997; 103:291–297
029 Yes 3 years 100 51.8 McClung M et al. Ann Intern Med 1998; 128:253–261
035 Yes 3 years 100 64.6 Tucci JR, et al. Am J Med 1996; 101:488–501
037 Yes 3 years 100 62.6 Devogelaer JP, et al. Bone 1996; 18:141–150
038 Yes 2 years 100 52.2 Adami S et al. Osteopor Intl 1993; 3(Suppl 3):S21–S27
041 Yes 6 months 100 59.5 Adami S et al. Bone 1995; 17:383–390
051.1 Yes 3 years 100 70.8 Black DM, et al. Lancet 1996; 348:1535–1541
(FIT vertebral fractures)
051.2 Yes 4 years 100 68.1 Cummings SR, et al. JAMA 1998; 280:2077–2082
(FIT clinical fractures)
054 Yes 2 years 100 70.8 Bone HG, et al. J Clin Endocrinol Metab 1997;
82:265–274
055 Yes 6 years 100 53.3 Hosking D, et al. N Engl J Med 1998; 338:485–492
(EPIC)
057 Yes 2 years 100 69.9 Greenspan SL, et al. J Bone Miner Res 1998;
13:1431–1438
063 Yes 2 years 100 66.1 Bell NH, et al. J Clin Endocrinol Metab 2002;
87:2792–2797
072 Yes 2 years 100 61.3 Bone HG, et al. J Clin Endocrinol Metab 2000;
85:720–726
082 Yes 1 year 69.5 54.7 Saag KG, et al. N Engl J Med 1998; 339:292–299
083 Yes 1 year 67.2 56.0 Saag KG, et al. N Engl J Med 1998; 339:292–299
087 Yes 6 months 100 78.5 Greenspan SL, et al. Ann Intern Med 2002;
136:742–746
088 Yes 6 months 100 66.2 Bonnick SL, et al. Curr Med Res Opin 2007;
23:1341–1349 (INPACT)
095 Yes 1 year 43.9 46.0 van der Poest CE, et al. J Bone Miner Res 2002;
17:2247–2255
096 Yes 2 years 0 62.7 Orwoll E, et al. N Engl J Med 2000; 343:604–610
097 Yes 1 year 100 61.7 Lindsay R, et al. J Clin Endocrinal Metab 1999;
84:3076–3081 (FACET)
104 Yes 1 year 100 64 Downs RW Jr, et al. J Clin Endocrinol Metab 2000;
85:1783–1788 (FOCAS)
109 Yes 1 year 100 65 Data on file (inFOCAS)
112 Yes 2 years 51 50.5 Jeffcoat MK, et al. In: Davidovitch Z, Norton LA (eds)
Biological mechanisms of tooth movement and
craniofacial adaptation. Harvard Society for the
Advancement of Orthodontics, Boston, 1996:365–373
117 Yes 6 months 36.6 63 Rubash H, et al. 50th annual meeting of the Orthopaedic
Research Society [Abstract]. Transactions 2004;
29:1942
159 Yes 1 year 100 69.2 Hosking D, et al. Curr Med Res Opin 2003; 19:383–394
162 Yes 12 weeks 92.4 66.7 Greenspan S, et al. Mayo Clin Proc 2002;
77:1044–1052
165 Yes 1 year 0 66.1 Miller PD, et al. Clin Drug Invest 2004; 24:333–341
193 Yes 1 year 58.4 52.9 Stoch S, et al. J Rheumatol 2009; 36:1705–1714
219 Yes 6 months 100 65.2 Cryer B, et al. Am J Geriatr Pharmacother 2005;
3:127–136 (OASIS)
901 Yes 1 year 100 62.8 Pols HA, et al. Osteoporos Int 1999; 9:461–468 (FOSIT)
902 Yes 1 year 100 57.3 Ascott-Evans BH, et al. Arch Intern Med 2003;
163:789–794
904 Yes 12 weeks 94.2 63.6 Eisman JA, et al. Curr Med Res Opin 2004; 20:699–705
Osteoporos Int (2012) 23:233–245 235clinical pharmacology studies without a placebo compara-
tor, and none had any AF events. Treatment groups with
daily doses of <5 mg were excluded because the lower-dose
studies could bias toward the null even if there were a true
causal relationship. Treatment groups with daily doses
>20 mg were also excluded. Only studies conducted by
Merck or for Merck by a contract research organization
were included. Extension studies were included for the AE
analysis if participants were still blinded to treatment
allocation and remained on the same treatment and if there
was a placebo group for comparison. In FLEX, the long-
term extension of FIT, participants from FIT, after an
average of 5 years of prior alendronate therapy, were
randomized to one of three treatment arms for an additional
5 years: 10 mg alendronate, 5 mg alendronate, or placebo.
Although FLEX was not included in the meta-analysis,
because all participants had previously received alendronate
for ~5 years, data for AF AEs in FLEX are summarized
separately because of the large patient population. For each
study included in the analysis, all study groups with doses
of alendronate within the pre-specified range were com-
bined to form a single pooled “alendronate” group.
Changes of alendronate dose within the pre-specified range
were not distinguished. All participants treated with
placebo following active treatment or active treatment
following placebo were included until the change of
treatment. The two cohorts of FIT, the vertebral fracture
cohort (identified as study 51.1) and the clinical fracture
cohort (identified as study 51.2), were two trials within a
single protocol, but were analyzed as two separate studies.
Statistical methods
The studies included in this meta-analysis span several
years, and data from different studies were collected using
different methods and databases. Because of this, patient-
level time-to-event data were not always available to
conduct the analyses described here. Meta-analysis was
used to calculate a weighted average from the individual
studies. The primary method of analysis for all endpoints
was exact Poisson regression. An estimate for the relative
risk of alendronate versus placebo and the associated 95%
confidence interval (CI) was derived from a model that
included the number of episodes with factors for treatment
group and study and an offset parameter for the number of
person-years on study. The exact number of person-years of
follow-up for each treatment group within each trial was
calculated using patient-level information utilizing the first
and last treatment date on study drug. The relative risk and
associated confidence intervals were reported for each
study from the exact Poisson regression model with a
factor for treatment. When zero events occurred in the
placebo group, the relative risk for the study was undefined
and could not be calculated. In isolated cases, the statistical
analysis procedure could not calculate confidence intervals
for the relative risk due to the absence of events; in those
cases, the relative risk alone was reported as a summary
statistic.
The odds ratio was reported from a fixed-effects meta-
analysis model using Mantel–Haenszel methods with a
Robins–Breslow–Greenlandvariance.Acontinuitycorrection
Table 1 (continued)
Study Included
in meta-
analysis
If excluded—reason
for exclusion
Length
of study
Percent
women
Average age
for study (in
years)
Citation
056 No Paget’s disease 6 months 34.8 69.0 Siris E, et al. J Clin Endocrinol Metab 1996;
81:961–967
059 No Paget’s disease:
alendronate dose
above allowable
range
6 months 43.6 69.9 Reid IR, et al. Am J Med 1996; 101:341–348
118 No No placebo
comparator
2 years 100 66.5 Rizzoli R, et al. J Bone Miner Res 2002; 17:1988–1996
119 No No placebo
comparator
1 year 100 56.2 Luckey MM, et al. Obstet Gynecol 2003; 101:711–721
189 No No placebo
comparator
1 year 100 64.2 Luckey M, et al. Menopause 2004; 11:405–415
(EFFECT)
211 No No placebo
comparator
2 years 100 64.4 Rosen CJ, et al. J Bone Miner Res 2005; 20:141–151
(FACT)
227 No No placebo
comparator
15 weeks 95.1 66.8 Recker R, et al. Curr Med Res Opin 2006;
22:1745–1755
906 No No placebo
comparator
1 year 100 61.7 Sambrook PN, et al. J Intern Med 2004; 255:503–511
907 No No placebo
comparator
1 year 100 64.1 Reid DM, et al. Clin Drug Invest 2006; 26:63–74
236 Osteoporos Int (2012) 23:233–245factor (CCC), to account for studies with zero events, was
added to the placebo cells, and a treatment correction factor
(TCC) was added to the alendronate cells in each cell of the
2×2table,proportionaltothe reciprocaloftheother treatment
group and such that TCC+CCC=0.01 [12]. The odds ratio
was reported for each study and could not be calculated
when zero events occurred in the placebo group. When zero
events occurred only in the alendronate group of the study,
the odds ratio was zero. Both the relative risk and the odds
ratio were reported to provide a more complete perspective
of the data set.
A test for heterogeneity was conducted using the
treatment-by-study interaction term in exact Poisson re-
gression model. The stability of the estimates was evaluated
by conducting exact Poisson regression meta-analysis with
each study eliminated one at a time and by constructing
estimates within pre-specified subgroups as below:
1. Age: Average study age ≤65, >65 years
2. Elderly participants (mean age of 70 years) (yes, no):
Elderly study—Protocol 054 (mean age 70.8 years),
FIT vertebral fracture study—Protocol 51.1 (mean age
70.8 years), Nursing home study—Protocol 087 (mean
age 78.5 years) vs. all other studies (mean age
68.5 years)
3. Studies for the prevention of osteoporosis (Protocols
029, 038, and 055) were grouped together. A second
group comprised protocols 035, 037 (the original Phase
III studies), and 051 (Phase III study for the subsequent
fracture endpoint), all similarly designed long-term
studies for the treatment of osteoporosis rather than
prevention. All other studies comprised the third group.
4. Length of study: ≤1 year, >1 year
These meta-analyses are exploratory in nature. No multi-
plicity adjustments were made.
Assuming an incidence rate of five per 1,000 person-
years (the incidence observed in the placebo group), the
18,000 person-years in the two treatment groups is
sufficient to detect a 50% increase in the alendronate group
with more than 90% power assuming a one-sided signifi-
cance level or 85% power assuming a two-sided signifi-
cance level. The 18,000 person-years in the two treatment
groups is sufficient to detect a 40% increase in the
alendronate group with more than 75% power assuming a
one-sided significance level.
Supplemental analyses in FIT
Additional post hoc analyses were performed in FIT to
further evaluate MI SAEs. Post hoc subgroup analyses of
this nature should be interpreted with caution because the
possibility of chance findings increases whenever multiple
analyses are performed. In this analysis, the investigators’
original reported diagnosis was included by default in cases
where the adjudicated consensus was “insufficient data.”
Primary intention-to-treat analyses were applied to adjudi-
cated data. It was pre-specified that p values would not be
provided for adjudicated data, based on statistical issues
concerning potential misinterpretation in the context of a
post hoc assessment of this nature. Consequently, only
relative risks and 95% CIs are reported.
Results
Forty-one studies were considered for the meta-analysis.
Thirty-twostudies met all criteriafor inclusion inthe analysis,
including having alendronate participant groups within the
pre-specified dose range for alendronate (Table 1). The 32
studies represent 9,518 participants and 20,265 person-years
on alendronate, with an average of 2.13 person-years per
subject, and 7,773 participants and 18,018 person-years on
placebo, with an average of 2.32 person-years per subject.
Follow-up time ranged from 12 weeks for Studies 162 and
904 to 6 years for study 055.
Endpoint of atrial fibrillation or atrial flutter
All AF events (atrial fibrillation and atrial flutter)
The p value for the test for heterogeneity was 0.30 based on
the treatment-by-study interaction term in the Poisson
regression model. The estimated relative risk for all events
of AF (serious and non-serious combined) was 1.16 (95%
CI=0.87, 1.55; p=0.33; Fig. 1A) and was similar to the
estimated odds ratio for all events: 1.16 (95% CI=0.87,
1.53; p=0.32; Table 2). There were 112 events of AF
reported in the 9,518 participants taking alendronate
included in the analysis, occurring in 17 trials. Eighty-
nine events were reported in the 7,773 participants taking
placebo, occurring in 12 trials. In 24 trials, there were fewer
than two AF events in either treatment group; of these, 11
trials (34.4%) did not have any reported events of AF.
Results for atrial fibrillation without including atrial flutter
were similar, with only five events on alendronate and three
events on placebo attributed to atrial flutter alone (data not
shown). At the end of FLEX, there were eight AF events
with 1,398.6 patient-years in the 10-mg arm, 10 AF events
with 1,397.7 patient-years in the 5-mg arm, and 10 AF
events with 1,837.7 patient-years in the placebo arm.
Serious AF events
The p value for the test for heterogeneity was 0.13 based on
the treatment-by-study interaction term in the Poisson
regression model. The estimated relative risk for AF SAEs
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B. 
Study 26
Study 29
Study 35
Study 37
Study 38
Study 41
Study 51.1
Study 51.2
Study 54
Study 55
Study 57
Study 63
Study 72
Study 82
Study 83
Study 87
Study 88
Study 95
Study 96
Study 97
Study 104
Study 109
Study 112
Study 117
Study 159
Study 162
Study 165
Study 193
Study 219
Study 901
Study 902
Study 904
Meta-analysis
Study 
*Expressed as alendronate versus placebo
0.01 0.1 1 10 100
RR* (95% CI Fixed)
Undefined
Undefined
Undefined
Undefined
Undefined
Undefined
1.14 (0.63,  2.08)
1.15 (0.77,  1.72)
0.00 (-INF,  5.60)
Undefined
Undefined
Undefined
Undefined
0.47 (0.01, 37.11)
1.00 (0.05, 59.27)
1.28 (0.32,  5.28)
0.62 (0.10,  6.50)
Undefined
0.00 (-INF, 24.81)
Undefined
Undefined
Undefined
Undefined
Undefined
0.52 (0.01, 40.77)
0.00 (-INF, 38.66)
Undefined
0.00 (-INF, 21.38)
Undefined
1.04 (0.01, 81.34)
Undefined
Undefined
1.16 (0.87,  1.55)
Relative risk of all events
(95% CI)
Study 26
Study 29
Study 35
Study 37
Study 38
Study 41
Study 51.1
Study 51.2
Study 54
Study 55
Study 57
Study 63
Study 72
Study 82
Study 83
Study 87
Study 88
Study 95
Study 96
Study 97
Study 104
Study 109
Study 112
Study 117
Study 159
Study 162
Study 165
Study 193
Study 219
Study 901
Study 902
Study 904
Meta-analysis
Study 
*Expressed as alendronate versus placebo
0.01 0.1 1 10 100
RR* (95% CI Fixed)
Undefined
Undefined
Undefined
Undefined
Undefined
Undefined
1.37 (0.62,  3.15)
1.56 (0.86,  2.89)
0.00 (-INF,  5.60)
Undefined
Undefined
Undefined
Undefined
0.00 (-INF, 18.44)
Undefined
0.71 (0.06,  6.19)
0.74 (0.06, 38.98)
Undefined
0.00 (-INF, 24.81)
Undefined
Undefined
Undefined
Undefined
Undefined
0.00 (-INF, 20.26)
Undefined
Undefined
Undefined
Undefined
Undefined
Undefined
Undefined
1.25 (0.82,  1.93)
Relative risk of serious events
(95% CI)
Fig. 1 Relative risk (RR) of all
events (A) or serious events (B)
of atrial fibrillation or flutter in
placebo-controlled trials of
alendronate conducted by Merck.
Study 51.1 is the vertebral
fracture cohort of FIT, and study
51.2 is the clinical fracture cohort
of FIT. Undefined indicates
that there were no AF events in
the placebo arm of the study,
although there may have been an
event in the alendronate arm.
0.00 indicates that there were no
AF events in the alendronate arm
and at least one AF event in the
placebo arm
238 Osteoporos Int (2012) 23:233–245Table 2 Odds ratio (expressed as alendronate versus placebo) of atrial fibrillation or atrial flutter by study and treatment arm
Study Treatment
a N Person-
years
History of atrial fibrillation
or atrial flutter n (%)
All events
n (%)
Serious
events n (%)
Odds ratio of
all events
Odds ratio of
serious events
026 Alendronate 94 140.06 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
026 Placebo 31 51.75 0 (0.00) 0 (0.00) 0 (0.00)
029 Alendronate 265 605.31 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
029 Placebo 90 213.28 0 (0.00) 0 (0.00) 0 (0.00)
035 Alendronate 286 753.89 1 (0.35) 0 (0.00) 0 (0.00) Undefined Undefined
035 Placebo 192 512.44 0 (0.00) 0 (0.00) 0 (0.00)
037 Alendronate 311 826.88 0 (0.00) 1 (0.32) 0 (0.00) Undefined Undefined
037 Placebo 205 540.85 1 (0.49) 0 (0.00) 0 (0.00)
038 Alendronate 235 254.52 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
038 Placebo 56 85.34 0 (0.00) 0 (0.00) 0 (0.00)
041 Alendronate 140 258.57 0 (0.00) 1 (0.71) 0 (0.00) Undefined Undefined
041 Placebo 71 130.48 0 (0.00) 0 (0.00) 0 (0.00)
51.1 Alendronate 1,022 2,719.89 12 (1.17) 27 (2.64) 17 (1.66) 1.16 1.40
51.1 Placebo 1,005 2,638.61 11 (1.09) 23 (2.29) 12 (1.19)
51.2 Alendronate 2,214 8,357.86 19 (0.86) 57 (2.57) 31 (1.40) 1.15 1.56
51.2 Placebo 2,218 8,430.05 20 (0.90) 50 (2.25) 20 (0.90)
054 Alendronate 93 155.70 0 (0.00) 0 (0.00) 0 (0.00) 0.00 0.00
054 Placebo 91 163.85 0 (0.00) 2 (2.20) 2 (2.20)
055 Alendronate 498 1,548.97 1 (0.20) 1 (0.20) 0 (0.00) Undefined Undefined
055 Placebo 502 1,914.93 0 (0.00) 0 (0.00) 0 (0.00)
057 Alendronate 59 132.70 0 (0.00) 1 (1.69) 1 (1.69) Undefined Undefined
057 Placebo 60 128.51 1 (1.67) 0 (0.00) 0 (0.00)
063 Alendronate 32 59.96 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
063 Placebo 33 59.48 0 (0.00) 0 (0.00) 0 (0.00)
072 Alendronate 232 514.49 1 (0.43) 3 (1.29) 1 (0.43) Undefined Undefined
072 Placebo 193 412.14 0 (0.00) 0 (0.00) 0 (0.00)
082 Alendronate 164 147.32 2 (1.22) 1 (0.61) 0 (0.00) 0.49 0.00
082 Placebo 81 69.66 0 (0.00) 1 (1.23) 1 (1.23)
083 Alendronate 154 125.02 4 (2.60) 2 (1.30) 0 (0.00) 1.01 Undefined
083 Placebo 78 62.80 4 (5.13) 1 (1.28) 0 (0.00)
087 Alendronate 165 239.48 10 (6.06) 6 (3.64) 2 (1.21) 1.18 0.65
087 Placebo 162 254.52 6 (3.70) 5 (3.09) 3 (1.85)
088 Alendronate 563 887.87 6 (1.07) 5 (0.89) 3 (0.53) 0.61 0.73
088 Placebo 138 219.75 2 (1.45) 2 (1.45) 1 (0.72)
095 Alendronate 21 18.79 0 (0.00) 1 (4.76) 0 (0.00) Undefined Undefined
095 Placebo 20 17.74 0 (0.00) 0 (0.00) 0 (0.00)
096 Alendronate 146 267.64 1 (0.68) 0 (0.00) 0 (0.00) 0.00 0.00
096 Placebo 95 170.24 1 (1.05) 1 (1.05) 1 (1.05)
097 Alendronate 214 214.70 1 (0.47) 0 (0.00) 0 (0.00) Undefined Undefined
097 Placebo 214 207.70 1 (0.47) 0 (0.00) 0 (0.00)
104 Alendronate 118 96.97 3 (2.54) 1 (0.85) 0 (0.00) Undefined Undefined
104 Placebo 58 51.10 0 (0.00) 0 (0.00) 0 (0.00)
109 Alendronate 108 99.66 1 (0.93) 1 (0.93) 0 (0.00) Undefined Undefined
109 Placebo 58 50.85 0 (0.00) 0 (0.00) 0 (0.00)
112 Alendronate 167 273.29 0 (0.00) 2 (1.20) 0 (0.00) Undefined Undefined
112 Placebo 168 271.45 0 (0.00) 0 (0.00) 0 (0.00)
117 Alendronate 45 20.60 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
117 Placebo 31 12.24 0 (0.00) 0 (0.00) 0 (0.00)
Osteoporos Int (2012) 23:233–245 239was 1.25 (95% CI=0.82, 1.93; p=0.33, Fig. 1B) and was
similar to the estimated odds ratio for all serious events of
1.24 (95% CI=0.87, 1.87; p=0.29; Table 2). There were 55
participants with one or more AF SAEs for alendronate
occurring in six trials compared with 41 events for placebo
occurring in eight trials. Twenty-two trials (68.8%) did not
have any AF SAEs. Results for atrial fibrillation without
including atrial flutter were similar (data not shown).
Sensitivity analysis
The stability of the estimates for all events and for SAEs
was evaluated by conducting exact Poisson regression
meta-analyses with each study eliminated one at a time.
The order of magnitude of the relative risk for all events of
AF changed very little as each study was eliminated,
although the 95% confidence interval became wider when
the large clinical fracture cohort of FIT, study 51.2, was
eliminated (Fig. 2A).
The two cohorts for FIT, which represent 34% of the
participants taking alendronate and 41% of the participants
taking placebo, experienced 87.3% of the AF SAEs for
alendronate and 78.0% of the AF SAEs for placebo. The
relative risk of AF SAEs including all studies was 1.25
(95% CI=0.82, 1.93), but became 0.97 (95% CI=0.51,
1.85) when the clinical fracture cohort of FIT, study 51.2,
was excluded (Fig. 2B), indicating that the results for
serious events were driven by the AF SAEs in that FIT
cohort [RR 1.56 (95% CI=0.86, 2.89) for AF SAEs in the
clinical fracture cohort]. In the vertebral fracture cohort
(study 51.1), the relative risk of AF SAEs was 1.37 (95%
CI=0.62, 3.15), but this cohort had a smaller contribution
to the overall results because it represented approximately
one third of the patient years of the clinical fracture cohort.
Figure 3 summarizes the relative risk of AF and serious
events of AF within the pre-specified subgroups. Both
cohorts for FIT are included in the >65 group for age,
length of study >1 year, and pivotal studies of osteoporosis.
The clinical fracture cohort of FIT is not included in the
elderly participants group because the average age was less
than 70 years old (mean age 61 years). The results of the
clinical fracture cohort of FIT overwhelm the results of the
other studies to the extent that the subgroup analyses reflect
the presence or absence of that cohort in the subgroup.
Other endpoints
The endpoints of CA, CVA, and CHF were examined in the
meta-analysis using the same studies and the same patient
populations as were used for the atrial fibrillation endpoint:
Table 2 (continued)
Study Treatment
a N Person-
years
History of atrial fibrillation
or atrial flutter n (%)
All events
n (%)
Serious
events n (%)
Odds ratio of
all events
Odds ratio of
serious events
159 Alendronate 219 187.10 3 (1.37) 1 (0.46) 0 (0.00) 0.49 0.00
159 Placebo 108 97.18 0 (0.00) 1 (0.93) 1 (0.93)
162 Alendronate 236 48.68 4 (1.69) 0 (0.00) 0 (0.00) 0.00 Undefined
162 Placebo 237 48.26 5 (2.11) 1 (0.42) 0 (0.00)
165 Alendronate 109 101.94 3 (2.75) 0 (0.00) 0 (0.00) Undefined Undefined
165 Placebo 58 50.15 0 (0.00) 0 (0.00) 0 (0.00)
193 Alendronate 114 91.16 1 (0.88) 0 (0.00) 0 (0.00) 0.00 Undefined
193 Placebo 59 49.97 0 (0.00) 1 (1.69) 0 (0.00)
219 Alendronate 224 102.38 4 (1.79) 0 (0.00) 0 (0.00) Undefined Undefined
219 Placebo 230 104.77 6 (2.61) 0 (0.00) 0 (0.00)
901 Alendronate 950 875.49 2 (0.21) 1 (0.11) 0 (0.00) 1.01 Undefined
901 Placebo 958 907.17 5 (0.52) 1 (0.10) 0 (0.00)
902 Alendronate 95 88.07 0 (0.00) 0 (0.00) 0 (0.00) Undefined Undefined
902 Placebo 49 39.57 0 (0.00) 0 (0.00) 0 (0.00)
904 Alendronate 225 49.94 3 (1.33) 0 (0.00) 0 (0.00) Undefined Undefined
904 Placebo 224 50.72 1 (0.45) 0 (0.00) 0 (0.00)
Odds ratio of all events 1.16 95% CI (0.87, 1.53) p value 0.316
Odds ratio of serious events 1.24 95% CI (0.83, 1.87) p value 0.290
%: n/N×100. Odds ratio reported for each study and summarized across studies using the Mantel–Haenszel method with a Robins–Breslow–
Greenland and with treatment correction factor (TCC) and control correction factor (CCC) proportional to the reciprocal of the other treatment arm
and such that TCC+CCC=0.01
aSummarized across doses included in the meta analysis
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Study 29
Study 35
Study 37
Study 38
Study 41
Study 51.1
Study 51.2
Study 54
Study 55
Study 57
Study 63
Study 72
Study 82
Study 83
Study 87
Study 88
Study 95
Study 96
Study 97
Study 104
Study 109
Study 112
Study 117
Study 159
Study 162
Study 165
Study 193
Study 219
Study 901
Study 902
Study 904
Meta-analysis
Study eliminated
*Expressed as alendronate versus placebo
3 1 0.8 0.6 0.4
RR* (95% CI Fixed)
1.16 (0.87, 1.55)
1.16 (0.87, 1.55)
1.16 (0.87, 1.55)
1.15 (0.86, 1.54)
1.16 (0.87, 1.55)
1.15 (0.86, 1.55)
1.17 (0.83, 1.64)
1.17 (0.76, 1.83)
1.19 (0.89, 1.59)
1.15 (0.86, 1.54)
1.15 (0.86, 1.54)
1.16 (0.87, 1.55)
1.13 (0.84, 1.52)
1.17 (0.87, 1.57)
1.16 (0.87, 1.56)
1.15 (0.86, 1.56)
1.18 (0.88, 1.58)
1.15 (0.86, 1.54)
1.18 (0.88, 1.58)
1.16 (0.87, 1.55)
1.15 (0.86, 1.54)
1.15 (0.86, 1.55)
1.14 (0.85, 1.53)
1.16 (0.87, 1.55)
1.17 (0.87, 1.57)
1.17 (0.88, 1.57)
1.16 (0.87, 1.55)
1.18 (0.88, 1.58)
1.16 (0.87, 1.55)
1.16 (0.87, 1.56)
1.16 (0.87, 1.55)
1.16 (0.87, 1.55)
1.16 (0.87, 1.55)
Relative risk of all events
(95% CI)
Study 26
Study 29
Study 35
Study 37
Study 38
Study 41
Study 51.1
Study 51.2
Study 54
Study 55
Study 57
Study 63
Study 72
Study 82
Study 83
Study 87
Study 88
Study 95
Study 96
Study 97
Study 104
Study 109
Study 112
Study 117
Study 159
Study 162
Study 165
Study 193
Study 219
Study 901
Study 902
Study 904
Meta-analysis
Study eliminated
*Expressed as alendronate versus placebo
3 1 0.8 0.6 0.4
RR* (95% CI Fixed)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.20 (0.72, 2.03)
0.97 (0.51, 1.85)
1.31 (0.85, 2.04)
1.25 (0.82, 1.93)
1.23 (0.80, 1.90)
1.25 (0.82, 1.93)
1.23 (0.80, 1.90)
1.29 (0.84, 2.00)
1.25 (0.82, 1.93)
1.29 (0.83, 2.02)
1.27 (0.83, 1.97)
1.25 (0.82, 1.93)
1.29 (0.84, 2.00)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.29 (0.84, 2.00)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
1.25 (0.82, 1.93)
Relative risk of serious events
(95% CI)
A. 
B. 
Fig. 2 Relative risk (RR) of all
events (A) or serious events (B)
of atrial fibrillation or atrial
flutter cross-validation by elimi-
nating one study at a time. For
example, the first RR represents
all trials except study 26, etc.
Study 51.1 is the vertebral
fracture cohort of FIT, and study
51.2 is the clinical fracture
cohort of FIT
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7,773 on placebo.
Cardiac arrhythmias
The estimated relative risk for all AEs of cardiac arrhythmia
(including AF) was 0.92 (95% CI=0.79, 1.07; p=0.31), and
the estimated odds ratio was 0.91 (95% CI=0.78, 1.06; p=
0.23). The estimated relative risk for SAEs was 1.18 (95%
CI=0.87, 1.61; p=0.31), and the estimated odds ratio was
1.17 (95% CI=0.87, 1.59; p=0.30). There were 360 AEs
and 98 SAEs of cardiac arrhythmia for alendronate,
occurring in 26 trials (Online Table A). There were 346
AEs and 78 SAEs of cardiac arrhythmia for placebo,
occurring in 24 trials. Thirty trials had at least one event
in either treatment group; two trials had no events. As
seen with the AF endpoint, FIT accounted for two thirds
of the arrhythmia events (study 51.1—alendronate=85,
placebo=78, RR=1.06; study 51.2—alendronate=159,
placebo=162, RR=0.99).
Non-hemorrhagic cerebrovascular accidents (CVA)
The estimated relative risk for all CVA AEs was 0.85 (95%
CI=0.65, 1.11; p=0.25), and the estimated odds ratio was
0.84 (95% CI=0.65, 1.10; p=0.21). There were 108 CVA
AEs for alendronate occurring in 11 trials, compared with
122 CVA AEs for placebo occurring in nine trials (Online
Age
(average age for study in years)
>65
≤65
Studies of elderly patients
Elderly patients
(054, 51.1, 087)
All other studies
Length of study (in years)
>1
≤1
Indication
Pivotal studies of osteoporosis
(035, 037, 051)
Osteoporosis prevention studies
(029, 038, 055)
Other osteoporosis studies
Subgroup
*Expressed as alendronate versus placebo
0.2 0.5 1 2 5 10
RR* (95% CI Fixed)
1.10 (0.81, 1.49)
2.11 (0.72, 7.52)
1.09 (0.64, 1.85)
1.20 (0.84, 1.71)
1.20 (0.87, 1.64)
0.97 (0.44, 2.17)
1.16 (0.84, 1.60)
Undefined
1.11 (0.56, 2.26)
Relative risk of all events
(95% CI)
Age
(average age for study in years)
>65
≤65
Studies of elderly patients
Elderly patients
(054, 51.1, 087)
All other studies
Length of study (in years)
>1
≤1
Indication
Pivotal studies of osteoporosis
(035, 037, 051)
Osteoporosis prevention studies
(029, 038, 055)
Other osteoporosis studies
Subgroup
*Expressed as alendronate versus placebo
0.2 0.5 1 2 5 10
RR* (95% CI Fixed)
1.31 (0.85, 2.04)
0.31 (0.01, 6.03)
1.10 (0.54, 2.26)
1.36 (0.78, 2.39)
1.41 (0.90, 2.24)
0.45 (0.10, 1.89)
1.49 (0.93, 2.41)
Undefined
0.49 (0.15, 1.55)
Relative risk of serious events
(95% CI)
A. 
B. 
Fig. 3 Relative risk (RR) of all
events (A) or serious events
(B) of atrial fibrillation or
atrial flutter within subgroups.
Undefined indicates that there
were no AF events in the placebo
arm of the study, although there
may have been an event in
the alendronate arm
242 Osteoporos Int (2012) 23:233–245Table A). Thirteen trials had CVA AEs; 19 trials had no
CVA events.
Congestive heart failure (CHF)
The estimated relative risk for all CHF AEs was 0.96 (95%
CI=0.71, 1.30; p=0.84), and the estimated odds ratio was
0.95 (95% CI=0.71, 1.28; p=0.75). There were 91 CHF
AEs for alendronate occurring in 11 trials compared with
91 AEs for placebo occurring in eight trials (Online
Table A). Thirteen trials had an AE in one or both treatment
groups; 19 trials had no CHF events.
Myocardial infarctions and cardiovascular deaths in FIT
As FIT was the largest trial included in this meta-analysis
and as it was the only trial to adjudicate CVAEs, only MIs
and CV deaths from FIT are summarized. An analysis of
the adjudicated results of all FIT SAEs attributed to
coronary heart disease (CHD) in the combined cohort did
not demonstrate a significant increase in risk of MI with
alendronate compared with placebo (1.4% vs. 1.1%, RR
1.28, 95% CI=0.82, 2.00). All CV deaths that occurred
during FIT, as well as all deaths reported with the term
“sudden death,” were included in the adjudication. There
were 23 CV deaths in the placebo group and 28 in the
alendronate group [RR=1.22 (95% CI=0.68, 2.21), p=
0.578 for alendronate vs. placebo]. Subgroups in CV deaths
were sudden/unknown (placebo=8, alendronate=9), fatal
MI (placebo=3, alendronate=6), cardiac non-myocardial
infarction, defined as an event unrelated to myocardial
ischemia (placebo=1, alendronate=7), and non-cardiac
(cardiovascular) (placebo=11, alendronate=6). The number
of deaths in the different subcategories was too small to
allow meaningful conclusions.
Discussion
In this meta-analysis of all Merck-conducted, placebo-
controlled clinical trials of alendronate, the occurrence of
AF was uncommon, with most studies reporting two or
fewer events. Across all studies, no clear association
between overall bisphosphonate exposure and the rate of
serious or non-serious AF was observed.
The present study included published and unpublished
data from all trials of alendronate of at least 3 months
duration meeting eligibility criteria selected prior to
analyses. The total number of individuals in the smaller,
shorter studies was similar to the total number enrolled in
FIT, permitting the comparison most relevant to determin-
ing whether AF was caused by the study medication or was
a chance association.
The analysis of rare event data is problematic. Poisson
regression, the method used here, assumes a constant
hazard rate over time, within each study. Given the small
number of events, the appropriateness of this assumption
within these studies would be hard to evaluate. Based on a
review of AF in FIT and the incidence of AF SAEs in the
HORIZON zoledronic acid trial, which were reported to
have occurred uniformly over time, the assumption of a
constant hazard rate over time is reasonable, however, and
the summary measure of the event rate per patient-year of
follow-up for each trial appears to be appropriate. In
addition, most commonly used methods of meta-analysis
(log-odd or log risk ratio) become undefined when zero
events occur in either or both groups of a study [13, 14].
Standard statistical software either eliminates these studies
completely or introduces correction factors that seriously
bias the results, but there is information to be gained about
absolute risks by including large or long-running studies
without any events.
The results of the current meta-analysis are in accord
with the findings of the FDA regarding all bisphosphonates,
which concluded that the incidence of AF was rare in
clinical trial data and that there was no clear association
between overall bisphosphonate exposure and the rate of
serious or non-serious atrial fibrillation [15]. Others who
have looked at the incidence of AF in bisphosphonate trials
since the initial reports by Black et al. [4] and Cummings
and colleagues [5] have reported no association, including
in a second trial of intravenous zolendronate [6–11].
Lewiecki et al. [10] analyzed pooled data from the four
pivotal trials of ibandronate and found no increased risk of
AF with any ibandronate regimen. Loke et al. [11]
conducted a systematic review of four datasets from
placebo-controlled RCTs and two case–control studies of
bisphosphonates and found no association of overall AF
with bisphosphonate use, but a modest association of AF
SAEs with use, driven by one of the zolendronic acid
(HORIZON) trials and the alendronate (FIT) trial. Although
some retrospective epidemiologic studies have seen evi-
dence of an increased risk of AF with bisphosphonate use
[16–18], others have found that long-term risk of AF with
bisphosphonates did not differ from risk with raloxifene use
[19] or with no bisphosphonate use [20–22]. Vestergaard et
al. examined the effect of heart disease and lung disease on
the association between oral bisphosphonate use and AF in
a cohort study using the Danish National Hospital Dis-
charge Register and found that any excess risk of AF
became non-significant when chronic obstructive pulmo-
nary disease was introduced as a confounder [23].
In the present analysis, the FIT clinical fracture cohort is
the only trial of oral alendronate that suggested a potential
increased risk of serious AF [p=0.07; 47 events (1.5%) for
alendronate and 31 events (1.0%) for placebo over an
Osteoporos Int (2012) 23:233–245 243average of 4 years]. FIT was among the largest, longest oral
bisphosphonate trials and the only trial that prospectively
adjudicated all cases of AF. FIT had approximately the
same number of subjects as all other trials combined.
Further analyses of the data from the combined cohort of
FIT showed that all (serious plus non-serious) AF AEs, as
well as all arrhythmia AEs, were approximately balanced
between the groups, making the possibility of a true
association between AF and alendronate treatment unlikely.
It is not surprising that osteoporosis and AF occur
together in the elderly, as the prevalence of both increases
with age. Individuals with osteoporosis tend to be older and
have more cardiovascular disease, which may contribute to
the appearance of an increased risk of AF with bisphosph-
onate treatment seen in observational studies [16, 19, 22,
24, 25].
Overall, our data do not support a causal relationship
between alendronate and AF, as a (non-significant) trend
was observed in only a single randomized alendronate
clinical study. Furthermore, there is no plausible mecha-
nism for such an association. There was no clear evidence
that oral bisphosphonates caused calcium/electrolyte imbal-
ance in the blood (e.g., hypocalcemia), a hypothetical
mechanism proposed by Heckbert et al. [16], or any other
clinical AE that is a known risk factor for AF. There has
been speculation about other potential mechanisms [26,
27]. For example, AF and CHF are commonly co-existent
conditions that can contribute to the de novo development
or worsening of the other [28], but there does not appear to
be any evidence for an excess of heart failure in the
bisphosphonate-treated population.
Examination of other CV endpoints in the current meta-
analysis showed that there were no significant differences
in the risk of serious or all (serious plus non-serious) AEs
between the placebo and alendronate groups. These results
are similar to those found in FIT, which showed that other
AEs related to embolic or thrombotic disease, MIs and CV
deaths, were generally either evenly distributed or, in some
cases, occurred at higher frequency in participants on
placebo versus alendronate.
There are some limitations to this meta-analysis. Trial-
level data from multiple studies were pooled retrospectively
for analysis. Although performing a pooled analysis of
individual patient data would have been optimal had it been
available, two groups have shown that summary estimates
obtained from trial-level aggregated data and pooled
individual patient data appear to be equivalent when based
on the same studies under the same assumptions [29, 30].
Many CV AEs were adjudicated only in FIT. In the other
trials, the recorded AEs were extracted from investigator
reports of AEs in each study and are subject to reporting
bias. Standard regulatory definitions of “serious” AEs were
applied in all cases; however, the application of the
“serious” rating may be subjective when there were
multiple potentially “serious” AEs associated with a
hospitalization and was dependent on the individual blinded
investigator’s judgment.
In summary, the incidence of atrial fibrillation was
uncommon in these older participants in clinical trials of
alendronate and did not differ significantly between
alendronate and placebo groups. Based on this analysis,
alendronate use did not show evidence of an increased risk
of atrial fibrillation.
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